How to Use WebEx Q & A

1. Open the Q&A panel
2. Select “All Panelists”
3. Type your question
4. Click “Send”
Moderator/Presenter

**Leila Barraza**, Senior Consultant, Network for Public Health Law – Western Region Office; Associate Professor, Zuckerman College of Public Health

- J.D., Arizona State University – Sandra Day O’Connor College of Law
- M.P.H., University of Arizona – Zuckerman College of Public Health
Presenter

Jennifer Piatt, Senior Attorney, Network for Public Health Law – Western Region Office; Research Scholar, ASU Center for Public Health Law & Policy

- J.D., Arizona State University – Sandra Day O’Connor College of Law
Doug Campos-Outcalt, Senior Lecturer, Mel and Enid Zuckerman College of Public Health, University of Arizona; Clinical Professor, College of Medicine – Phoenix, University of Arizona

- M.D., University of Arizona
- M.P.A, Arizona State University
COVID-19 Vaccine Distribution: Legal Issues and Challenges

December 10, 2020   |  2:00 – 3:00 PM ET
“We are committed to expediting the development of COVID-19 vaccines, but not at the expense of sound science and decision making. We will not jeopardize the public’s trust in our science-based, independent review of these or any vaccines. There’s too much at stake.”

Stephen M. Hahn, M.D., FDA Commissioner, and Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research

Current & Emerging Challenges

Topics

- Allocation
- Authorization
- Liability
- Administration
- Storage
- Vaccine Hesitancy
- Two-Dose Requirement
COVID-19 Vaccine: Legal Implications

A “Top Ten” List of Legal Issues

Jennifer L. Piatt, JD
COVID-19 Confirmed Cases & Deaths

Global Cases  68.3 million | Deaths: 1.5 million
U.S. Cases     15.2 million | Deaths: 286,443
U.S. Stats     22% all cases | 19% all deaths

Once a vaccine is authorized, how is it allocated, and what legal issues result?
Phase 1
- "Jumpstart Phase"
  - High-risk health workers
  - First responders

Phase 1b
- People of all ages with comorbid and underlying conditions that put them at significantly higher risk
- Older adults living in congregate or overcrowded settings

Phase 2
- K–12 teachers and school staff and child care workers
- Critical workers in high-risk settings—workers who are in industries essential to the functioning of society and at substantially higher risk of exposure
- People of all ages with comorbid and underlying conditions that put them at moderately higher risk
- People in homeless shelters or group homes for individuals with disabilities, including serious mental illness, developmental and intellectual disabilities, and physical disabilities or in recovery, and staff who work in such settings
- People in prisons, jails, detention centers, and similar facilities, and staff who work in such settings
- All older adults not included in Phase 1

Phase 3
- Young adults
- Children
- Workers in industries and occupations important to the functioning of society and at increased risk of exposure not included in Phase 1 or 2

Phase 4
- Everyone residing in the United States who did not have access to the vaccine in previous phases

**Equity is a crosscutting consideration:** In each population group, vaccine access should be prioritized for geographic areas identified through CDC's Social Vulnerability Index or another more specific index.

**NATIONAL ACADEMY OF MEDICINE**

**The National Academies of SCIENCES • ENGINEERING • MEDICINE**
ACIP Interim Recommendation

“When a COVID-19 vaccine is authorized by FDA and recommended by ACIP, vaccination in the initial phase of the COVID-19 vaccination program (Phase 1a) should be offered to both (1) health care personnel and (2) residents of long-term care facilities.”

Health care personnel are defined as paid and unpaid persons serving in health care settings who have the potential for direct or indirect exposure to patients or infectious materials.

Long-term care facility residents are defined as adults who reside in facilities that provide a variety of services, including medical and personal care, to persons who are unable to live independently.

December 1, 2020 Interim Recommendation
## 10 Core Legal Issues Regarding COVID-19 Vaccine Allocation

1. Relevance of Ongoing Emergency Declarations at all Governmental Levels
2. Legal Challenges to the Allocation Scheme
3. FDA Approval and EUA Authorization Process
4. Federal Agency Authority over State, Tribal, & Local Governments
5. State Mandates to Vaccinate
6. Employer Mandates
7. Vaccine Exemptions
8. Informed Consent
9. Liability Protections for Providers & Entities
10. Compensation for Injuries Resulting from Vaccination
Relevance of Ongoing Emergency Declarations

- Suspend statutes & regulations
- Broad authority to exercise police powers
- Isolation & quarantine powers
- Rationing medicine & vaccinations
- Commandeer & use property
- Direction of state agency action
Who can provide vaccines?

Emergency SOP

Scope of Practice
Legal Challenges to the Allocation Scheme Itself

**STATE CHALLENGES**

Federalism

Federal Powers

- Declaring war
- Establishing Foreign Policy
- Regulating Interstate and Foreign Trade

State Powers

- Raising taxes
- Chartering banks
- Establishing Local Governments
- Regulating Intrastate Trade
- Providing for Public Safety
- Raising taxes
- Chartering banks
- Establishing Local Governments
- Regulating Intrastate Trade
- Providing for Public Safety

**INDIVIDUAL CHALLENGES**

Equal Protection Clause

No state shall deny to any person “equal protection of the law”
*EUAs:* FDA evaluates evidence available, balancing known risks with known benefits, to determine whether the product “may be effective”
FDA Approval and EUA Authorization Process

White House Blocks New Coronavirus Vaccine Guidelines

The F.D.A. proposed stricter guidelines for emergency approval of a coronavirus vaccine, but the White House chief of staff objected to provisions that would push approval past Election Day.

The New York Times

White House clears Food and Drug Administration coronavirus vaccine standards it tried to derail

The action comes after the FDA unilaterally published the criteria Tuesday morning.
Federal Authority over State, Tribal & Local Governments

Some states plan to vet Covid-19 vaccines themselves. Bad idea, experts say.
California and at least five other states have said they may independently vet any vaccines, but experts warn that could needlessly confuse the public.

Federal Approval ≠ State Acceptance

Exclusive: Most U.S. states reject Trump administration's new COVID-19 testing guidance
State Mandates to Vaccinate

State Police Powers
Allow states to legislate and regulate to protect, preserve, and promote health, safety, morals, and general welfare

Example:
Attendance at schools conditioned on vaccination completion
Employer Mandates

PRIVATE SECTOR MANDATES

Example:
Vaccination of health care workers in order to provide services at a hospital workplace

Equal Employment Opportunity Commission
- Religious/Disability Accommodations

Occupational Safety & Health Administration
- Provide a safe workplace
Vaccine Exemptions

EXEMPTIONS
Exemptions to mandated vaccinations vary widely across states; medical exemptions exist in all states, religious exemptions exist in most, and moral exemptions exist in several.

Roman Catholic Diocese of Brooklyn v. Cuomo (U.S. Supreme Court, November 25, 2020)

- Potential implications regarding religious exemptions
Informed Consent Provisions

“Every human being of adult years and sound mind has a right to determine what shall be done with his own body. . . .” N.Y. Court of Appeals Judge Benjamin Cardozo (1914)
**Liability Protections for Providers and Entities**

**CARES ACT**

“Good Samaritan” provision protects from civil liability interstate volunteer HCWs responding to the COVID-19 public health emergency

Explicitly overrides all state laws except those that provide even greater protection from liability

(Appplies to volunteers ONLY; does not cover willful or criminal conduct)

**PREP ACT**

Authorizes HHS Secretary to provide immunity to certain individuals and entities against loss claims arising out of the manufacture, distribution, administration, or use of a “covered countermeasure” in response to a public health emergency

(Appplies to all covered HCWs; does not cover willful misconduct)
Liability Protections for Providers and Entities

“Covered Persons who are afforded liability protections under this Declaration [include] . . . ‘qualified persons,’ as . . . defined in the PREP Act; their officials, agents, and employees; and the United States.

In addition, I have determined that the following additional persons are qualified persons: . . .

A State-licensed pharmacist who orders and administers, and pharmacy interns who administer . . . (1) vaccines that the Advisory Committee on Immunization Practices (ACIP) recommends to persons ages three through 18 according to ACIP’s standard immunization schedule or (2) FDA-authorized or FDA-licensed COVID-19 vaccines to persons ages three or older. . . .

Healthcare personnel using telehealth to order or administer Covered Countermeasures for patients in a state other than the state where the healthcare personnel are licensed or otherwise permitted to practice."

December 3, 2020 amendment to PREP Act Declaration
Compensation for Injuries

National Vaccine Injury Compensation Program provides compensation for injuries caused by routinely-administered vaccinations.

Countermeasures Injury Compensation Program (CICP) provides reimbursement of reasonable medical expenses, loss of income, or survivor benefits for individuals seriously injured/killed by countermeasures implemented under PREP Act.
Vaccines

How We Assure Safety and Effectiveness in the Age of COVID

Doug Campos-Outcalt MD, MPA
Disclosures

- Former member of the ACIP
  - 5 years as liaison
  - 4 years as voting member

- Current Consultant to the ACIP on GRADE assessments and ETR process.
Learning Objectives

• Describe:
  • The FDA process for approving vaccines
  • The Federal Structure for assessing vaccine safety.
  • How vaccine recommendations are made and where they can be located.
  • The federal system for compensating those affected by rare, serious, vaccine-related adverse events.
  • How this system will relate to the pending COVID vaccines.
<table>
<thead>
<tr>
<th>Candidate</th>
<th>Manufacturer</th>
<th>Type</th>
<th>Phase</th>
<th>Trial characteristics</th>
<th>Trial #</th>
<th>Recruiting</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRNA-1273</td>
<td>Moderna TX, Inc.</td>
<td>mRNA</td>
<td>III</td>
<td>2 doses (0, 28d) • IM administration • 18-55, 56+ years</td>
<td>NCT04470427</td>
<td>Enrollment complete</td>
</tr>
<tr>
<td>mRNA-BNT162</td>
<td>Pfizer, Inc./BioNTech</td>
<td>mRNA</td>
<td>II/III</td>
<td>2 doses (0, 21d) • IM administration • 18-85 years</td>
<td>NCT04368728</td>
<td></td>
</tr>
<tr>
<td>AZD1222</td>
<td>University of Oxford/AstraZeneca consortium*</td>
<td>Viral vector (NR)</td>
<td>III</td>
<td>2 doses (0, 28d) • IM administration • ≥18 years</td>
<td>NCT04516746</td>
<td>✓</td>
</tr>
<tr>
<td>Ad26COV51</td>
<td>Janssen Pharmaceutical Companies</td>
<td>Viral vector (NR)</td>
<td>III</td>
<td>1 dose • IM administration • 18-55, 65+</td>
<td>NCT04436276</td>
<td>✓</td>
</tr>
<tr>
<td>--</td>
<td>Sanofi/GSK</td>
<td>Protein Subunit</td>
<td>I/II</td>
<td>Single or 2 doses • IM administration • 18-49, 50+</td>
<td>NCT04537208</td>
<td>✓</td>
</tr>
<tr>
<td>NVX-CoV2373</td>
<td>Novavax</td>
<td>Protein Subunit</td>
<td>I/II</td>
<td>2 doses (0, 21d) • IM administration • 18-84</td>
<td>NCT04368988</td>
<td></td>
</tr>
<tr>
<td>V591</td>
<td>Merck</td>
<td>Viral Vector</td>
<td>I/II</td>
<td>2 doses (1, 57d) • IM administration • 18-55</td>
<td>NCT04498247</td>
<td>✓</td>
</tr>
</tbody>
</table>

*As of October 27, 2020
**Currently on hold in US

Federal Advisory Committees Involved with Vaccine Oversight

Department of Health and Human Services

National Vaccine Advisory Committee

National Vaccine Program Office (NVPO)

NVAC Vaccine Safety Working Group

Centers for Disease Control and Prevention (CDC)

Health Resources and Services Administration

Vaccine Injury Compensation Program (VICP)

Food and Drug Administration (FDA)

Vaccines and Related Biologic Products Advisory Committee (VRBPAC)

Advisory Committee on Immunization Practices (ACIP)

ACIP Working Groups, including MMRV Vaccine Safety Working Group

Advisory Commission on Childhood Vaccines (ACCV)
FDA Approval

- Vaccines and Related Biological Products Advisory Committee (VRBPAC)
  - Reviews effectiveness and safety data
  - Makes recommendation to FDA

- Ways to speed up the process
  - Expedite
  - Emergency use authorization
  - Extended use authorization

- EUA requires regular approval for ongoing use
EUA

Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN threat agents when there are no adequate, approved, and available alternatives.
EUA Requirements

- The chemical, biological, radiological, or nuclear (CBRN) agent referred to in the March 27, 2020 EUA declaration by the Secretary of HHS (SARS-CoV-2) can cause a serious or life-threatening disease or condition.

- Based on the totality of scientific evidence available, including data from adequate and well controlled trials, if available, it is reasonable to believe that the product may be effective to prevent, diagnose, or treat such serious or life-threatening disease or condition that can be caused by SARS-CoV-2.

- The known and potential benefits of the product, when used to diagnose, prevent, or treat the identified serious or life-threatening disease or condition, outweigh the known and potential risks of the product.

- There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the disease or condition.
Criteria Set for EUA for COVID Vaccines

- An EUA for a COVID-19 vaccine may be requested to allow for the vaccine’s rapid and widespread deployment for administration to millions of individuals, including healthy people, following a planned interim analysis in an ongoing Phase 3 trial.

- A favorable benefit/risk determination to support issuance of an EUA in this scenario would require, in addition to adequate manufacturing information:
  - Efficacy data showing protection against SARS-CoV-2 infection or disease with a point estimate of least 50% vs. placebo comparator and an appropriately alpha-adjusted confidence interval lower bound >30%
  - At least half of Phase 3 study subjects followed for both safety and efficacy for at least 2 months following completion of the full vaccination regimen
  - Safety data from throughout clinical development (including well over 3,000 Phase 3 vaccine recipients) to evaluate reactogenicity, serious AEs, and AEs of special interest
  - Sufficient cases of severe COVID-19 to assess for signals of enhanced disease
After FDA Approval
Who Makes Vaccine Recommendations?

- Advisory Committee on Immunization Practices
  - CDC administered
  - DHHS appointments members
  - Public can attend and speak
  - Agendas, presentations and minutes are posted
ACIP Structure

- 15 voting members (including Chair)
  - Non-governmental members
  - 4 year terms - overlapping
  - ACIP Steering Committee nominates, OS DHHS selects
  - Chair - selected from current members
  - One consumer representative
  - Voting members screened for conflicts of interest

- 8 ex officio members – representing other government agencies (CMS, DOD, DVA, FDA, HRSA, IHS, NIH, NVPO); nonvoting *

- 30+ liaison organizations – representatives of professional societies and organizations responsible for vaccine development and immunization programs; nonvoting
ACIP Processes

- FACA committee
- Public meetings, 3 times a year, webcast
- Work groups meet between meetings
- CDC staff support
Factors Considered

- Burden of disease
  - Epidemiology
  - Morbidity
  - Mortality
- Evidence is assessed using GRADE
  - Evidence of effectiveness
  - Evidence of safety
- Cost effectiveness
- Implementation logistics
- Values and perceptions of providers and stakeholders
Location
CDC Headquarters, Atlanta, GA
Safety Monitoring After Approval
CDC Immunization Safety Office: Research and Surveillance Infrastructure

- Vaccine Adverse Event Reporting System (VAERS)
- Vaccine Safety Datalink (VSD) Project
  - Clinical Immunization Clinical Assessment (CISA)
    - Consultation to clinicians on safety concerns’
    - Research on clinical vaccine safety
    - 8 academic research center collaborative
  - FDA influenza safety
  - Military
  - General medical literature on vaccine safety
The Vaccine Adverse Event Reporting System (VAERS)

- The “early warning system” of vaccine safety surveillance

- A national passive surveillance system jointly operated by the CDC and the FDA; established in 1990

- Accepts reports from physicians, other health care providers, vaccine manufacturers, health departments, and the public
  - Some reporting legally mandated but most reports voluntary

- “Hypothesis generating”; seeking signals of potential concern regarding rare adverse events not detected in pre-licensure studies and/or occurring in special populations

- Subject to over and under reporting
Vaccine Safety Datalink

- Collaboration between CDC and 8 managed care organizations.
- Provides comprehensive medical and immunization histories for 8.8 million people annually.
- Tests hypotheses suggested by signals from VAERS or other sources and conducts vaccine safety surveillance in near real-time.
VSD

Vaccine Safety Datalink

9 participating integrated healthcare organizations

Data on over 12 million persons per year
COVID Vaccine Surveillance Enhancements

- **VAERS**
  - Addition of smart phone app reporting
  - List of adverse events of interest
  - COVID related SAE monitoring

- **VSD**
  - Rapid cycle analysis

- **Additional agencies**
  - FDA (BEST)
  - CMS (Medicare)
  - DOD
  - Indian Health Services
2a. FDA Biologics Effectiveness and Safety (BEST) System

- Several partners – Acumen, IBM Watson, IQVIA, OHDSI, HealthCore, Humana, Optum, Healthagen, MedStar, OneFlorida, and Academic organizations

- Represents variety of healthcare settings – inpatient, emergency department, outpatient, etc.

- Emphasis on inclusion of Electronic Health Record (EHR) data, some claims data and linked Claims-EHR data
National Vaccine Injury Compensation Program
VICP

- Covers child vaccines even if used for an adult
- DHHS, DOJ and courts
- No fault system of compensation for vaccine related injuries proven to be caused by vaccines
  - Table of known SAE’s developed by the NAM
- The system favors plaintiffs
  - Burden of proof less
  - Government concedes cases that are even possible
Countermeasure Injury Compensation Program

- Same concept as VICP
- A countermeasure is a vaccination, medication, device, or other item recommended to diagnose, prevent or treat a declared pandemic, epidemic or security threat.
- See Countermeasures Injury Compensation Program (CICP) | Official web site of the U.S. Health Resources & Services Administration (hrsa.gov)
In the U.S. we have:

- a secure supply of safe vaccines;
- a transparent method of making vaccine recommendations;
- a robust system to monitor vaccine safety;
- an efficient system to compensate those who experience a rare, serious adverse reaction to a vaccine.
Questions?
Questions, Thoughts, Comments

Thank you!

lbarraza@networkforphl.org  jennifer.piatt@asu.edu | @jen_piatt  dougco@arizona.edu
How to Use WebEx Q & A

1. Open the Q&A panel
2. Select “All Panelists”
3. Type your question
4. Click “Send”
Thank you for attending

For a recording of this webinar and information about future webinars, please visit networkforphl.org/webinars

COVID-19: Real-Time Guidance, Resources and Information
View resources & request assistance at networkforphl.org/covid19

You may qualify for CLE credit. All webinar attendees will receive an email from ASLME, an approved provider of continuing legal education credits, with information on applying for CLE credit for this webinar.